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Abstract
Background: The article presents the results of a clinical trial on the efficacy and safety of a novel pharmaceutical
composition in the form of vaginal suppositories containing diindolylmethane in the course of cervical
intraepithelial neoplasia (CIN) I–II conservative treatment. It offers an attractive drug therapy for more personalized
prevention of cervical cancer.
Methods: A total of 78 women of reproductive age were included. This was a multicenter, randomized, placebo-
controlled, double-blind, parallel-group trial with efficacy determined by histological evaluation of cervical biopsies.
The efficacy of active drug treatment (100 and 200 mg/day) in both treatment groups was significantly higher in
comparison with the placebo group, according to the primary efficacy end point (proportion of patients with
complete CIN regression after 90–180 days of the study drug treatment).
Results: The efficacies were 100.0 % (confidence interval (CI) 95 %: 82.35–100.00 %), 90.5 % (CI 95 %: 69.62–
98.83 %), and 61.1 % (CI 95 %: 35.75–82.70 %), for the high dose, low does, and placebo, respectively. Adverse
events in the placebo group were reported in 22 % of patients (CI 95 %: 7.5–43.7 %); in the first treatment group
(100 mg/day), adverse events were reported in 40.0 % of patients (CI 95 %: 21.1–61.3 %); in the second treatment
group (200 mg/day), adverse events were reported in 42.0 % of patients (CI 95 %: 22.1–63.4 %). The differences in
side effects between treatment groups treated with the active drug and placebo were statistically significant. No
serious adverse events were reported in any of the groups.
Conclusions: Thus, the use of diindolylmethane in the form of intravaginal suppositories can be effective in
patients with CIN I–II and is not accompanied by clinically significant side effects. This approach could be a better
option for young women with CIN I–II as it takes in attention their reproductive plans.
Trial registration: ID: ChiCTR-INR-15007497 (2 December 2015)
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Background
Cervical intraepithelial neoplasia (CIN) represents dys-
plastic changes in the cervical epithelium which tend to
develop over time and can lead to cervical cancer (CC)
[1]. There are 528,000 new cases of cervical cancer
across the world every year, half of which are fatal [2].
So, it is obvious that public health needs to improve its
cervical cancer prevention strategy. According to the
WHO classification (1995), there are three degrees of
CIN: mild (CIN I), moderate (CIN II), and severe (CIN
III) dysplasia. Any CIN stage is treated based on con-
temporary standards, but these standards could contain
a more personalized approach. This paper is focused on
the attempt to make cervical cancer prevention both
more preventive and more personalized.
It is known that the human papillomavirus (HPV) infec-
tion is a key causative factor of pathological changes in
the cervix leading to its neoplastic transformation. Inte-
gration of the viral DNA into the cellular genome leads to
an increased unregulated synthesis of viral E6 and E7
oncoproteins, which increases the risk of malignant trans-
formation of the cervical epithelium [3, 4]. DNA of high-
risk HPV types 16 and 18 is found in 50–80 % of samples
of the squamous cervical epithelium with signs of moder-
ate to severe dysplasia [5]. HPV has the potential to trigger
the irreversible process of carcinogenesis of the cervical
epithelium in cases where the immune system of an
infected woman is weakened. CIN I resolves spontan-
eously in 50–60 % of cases within 3 years. At the same
time, intraepithelial neoplasia develops within 2 years in
15–30 % of women infected with high-risk HPV [6], while
about 10–20 % of CIN III cases transform into invasive
cervical cancer [7].
Recently, there has been increasing evidence that the
oncogenic activity of E6 and E7 oncoproteins can, in
addition to the well-known mechanism, be realized
through interaction between the p53 and retinoblastoma
pRb proteins, as well as via epigenetic mechanisms. As it
is known, DNA methylation and histone deacetylation
causing epigenetic “silencing” of the tumor-suppressor
genes are the main methods of the epigenetic regulation
of gene activity [8]. Methylation is carried out using a
special enzyme—DNA methyltransferase (DNMT)—or,
rather, a family of three isoenzymes—DNMT1,
DNMT3a, and DNMT3b. The degree of histone acetyl-
ation is regulated by special enzymes—acetylases (his-
tone acetyltransferase (HAT)) and deacetylases (histone
deacetylase (HDAC)). Numerous epigenetic changes
were identified at all stages of carcinogenesis of the cer-
vix. It has been shown that the level of methylation of
tumor-suppressor genes increases with the progression
of CIN [9, 10]. According to other reports, the E6 onco-
protein activates the expression of DNA methyltransfer-
ase DNMT1 and suppresses the expression of the p53
tumor-suppressor protein in cervical epithelial cells in-
fected with HPV type 16 [11]. It has been found that the
E7 oncoprotein is also able to modulate the DNA
methylation mechanism. In a 2006 study [12], it was
demonstrated that the E7 protein of HPV type 16 binds
to DNMT1 in vitro and in vivo, stimulating the activity
of the enzyme. The E7 oncoprotein is able to bind his-
tone to deacetylase directly and recruit the enzyme to
promoters of tumor-suppressor genes. There is evidence
that this may lead particularly to the depression of IFN-
beta gene transcription, followed by the inhibition of
interferon production [13]. The E7 oncoprotein’s binding
to HDAC reduces its effect on the promoter of the E2F2
transcription factor, causing an increase in the latter’s
expression, leading to disruption of the cell cycle and
uncontrolled cell proliferation [13].
The hormonal (estrogen) factor is another well-known
pathogenetic factor in the development of CIN. In the
course of metabolic conversions, the cytochrome P450
enzymatic system produces hydroxyestradiol, which is
oxidized to estrone, followed by hydroxylation with the
formation of two main metabolites: 16α-hydroxyestrone
(16α-OHE1) and 2-hydroxyestrone (2-OHE1). It has
been shown that 16α-OHE1 binds firmly to the estrogen
receptor (ER) that induces hyperproliferation of epithe-
lial cells. An alternative pathway of estrogen metabolism
is 2-hydroxylation. It is associated with a reduced risk of
developing hormone-dependent tumors. The ratio of
metabolites 2-OHE1/16α-OHE1 ≥ 2:1 is considered opti-
mal to maintain the normal estrogen balance [14]. It is
known that the proliferation of HPV-infected cervical
epithelial cells is enhanced by increased levels of 16α-
OHE1 [15].
The most common treatment for CIN is a fast local
destruction or excision of the affected tissue, such as
loop electrosurgical excision procedure (LEEP) of the
cervix, cold-knife cone biopsy, laser ablation, or cryo-
therapy. These methods have proved their efficiency.
However, there is a risk of damaging the cervix when
using them. Beyond this, cervical excision has a negative
effect on pregnancy outcomes (ectopic pregnancies and
terminations, miscarriage in the second trimester), espe-
cially in those patients who are repeatedly exposed to
such procedures [16]. In addition, after such treatment,
there is a high rate of recurrence of the disease [17].
Along with local destructive methods of treatment, in
some cases, patients undergo immune stimulation ther-
apy with interferon. However, this approach does not
lead to stable clinical results in the majority of cases
[18]. Due to this, it seems appropriate to develop opti-
mal schemes of systemic and local pharmacological cor-
rection using targeted agents acting on the molecular
mechanisms of CIN pathogenesis and subsequent malig-
nant transformation.
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Indole-3-carbinol (I3C) and its stable metabolite 3,3′-
diindolylmethane (DIM) are substances with proven
multitarget activity affecting a wide range of molecular
mechanisms. They can significantly slow down, stop, or
even regress neoplastic processes in the cervical epithe-
lium [19, 20].
It has been shown that I3C and DIM have a specific
anti-estrogen effect by stimulating processes of estradiol
2-hydroxylation under the influence of cytochrome
P450, thereby increasing the overall concentration of 2-
OHE1, a physiological metabolite relative to 16α-OHE1,
an “aggressive” metabolite [21]. It was experimentally
confirmed that I3C and DIM inhibited the growth of
estrogen-sensitive tumors in vivo and displayed antitu-
mor activity in CIN patients [22–26]. DIM causes apop-
tosis and arrests the growth of virus-infected cervical
cancer cells in vitro and in vivo [27, 28]. Another im-
portant feature of DIM is its ability to inhibit tumor
stem cells selectively. According to recent studies, these
are the main cause of tumor recurrence and metastases
[29]. The epigenetic anticancer effect of DIM has been
proven. DIM causes DNA-demethylating activity and
has the ability to inhibit the activity of class I histone
deacetylases, restoring the activity of tumor-suppressor
genes [30, 31]. Also, previously detected DIM immuno-
modulating activity contributes to the potential revers-
ibility of the pathological changes to the cervix [23].
Therefore, DIM is active against multiple HPV-infected
cervical epithelial cells. The development of topical
DIM-based medications for CIN treatment is relevant
due to the possibility of achieving higher concentrations
of the active substance in the affected tissue, as well as
reducing the likelihood of adverse reactions due to
gastrointestinal tract exposure.
The purpose of this study was to investigate the effi-
cacy and safety of a new pharmaceutical formulation of
DIM used in the form of vaginal suppositories for treat-
ment of women diagnosed with CIN I–II. Despite CIN I
being rarely treated, we wanted to check whether a safe
and effective therapy for CIN I could be developed. The
main reason was that a possibly cheap and safe therapy
may become a common option for these patients in con-
trast to surgical treatment.
Methods
The study included 78 patients of reproductive age with
abnormal colposcopy findings and histological verifica-
tion of CIN I and/or CIN II. Common inclusion criteria
for all the patients were the following: written informed
consent to participate in this study; diagnosis of grades
1–2 cervical intraepithelial neoplasia (CIN I–II), histo-
logically verified; age of 18–39 years; ability to carry out
the procedures according to the trial protocol; no official
or other forms of relations to the persons involved in
the study interested in its outcomes; and consent to use
a barrier method of contraception (condoms) during the
whole period of the study. The barrier contraception
method was recommended in order to minimize concur-
rent genitourinary infection and to decrease the bias.
Exclusion criteria were the following: pregnancy or
breast-feeding, severe cervical intraepithelial neoplasia
(CIN III) or cancer in situ, malignant tumors of any
localization, infections of the genitourinary system in the
acute phase, diseases of the cardiovascular and nervous
system and/or concomitant renal or hepatic failure, posi-
tive syphilis or HIV tests, alcohol abuse and/or narcotic
or drug dependency, and intake of any investigational
drug within 30 days prior to first dose of the study drug.
The current clinical trial had a multicenter, random-
ized, placebo-controlled, double-blind design and was
carried out in three parallel groups. The trial was con-
ducted in 12 study sites located in the Russian Feder-
ation. The trial was approved by the Ministry of Health
(resolution number 399 dated 10 October 2012, http://
grls.rosminzdrav.ru/CIPermitionReg.aspx) and local
Ethics Committees of the study sites. The study’s
hypothesis on the effectiveness of the drug is that its use
should lead to a more frequent recovery from CIN com-
pared to a placebo. Recovery was defined as complete
elimination of CIN according to histological studies of
cervical biopsies. Thus, if the rate of recovery from CIN
by the end of the study in the placebo group and in each
of the two study groups is equal to h0, h1, and h2, re-
spectively, null and alternative hypotheses can be formu-
lated as follows:
For the comparison of placebo and DIM therapy in the
dose of 100 mg/day:
H01: h0 = h1, there are no treatment-dependеnt
differences in the incidence of CIN recovery.
H11: h0 ≠ h1, there are treatment-dependеnt
differences in the incidence of CIN recovery.
For the comparison of placebo and DIM therapy in the
dose of 200 mg/day:
H02: h0 = h2, there are no treatment-dependеnt
differences in the incidence of CIN recovery.
H12: h0 ≠ h2, there are treatment-dependеnt
differences in the incidence of CIN recovery.
The need to verify the hypothesis of the study was
used as a basis in order to perform calculations of the
proper sample size. Statistical power was taken as 80 %
(β = 0.2), and the significance level (α) was taken as 0.05
(two-tailed). As we were going to perform two pairwise
Holm-adjusted comparisons [32], the sample size was
calculated according to the lowest α/2 level = 0.025. It
was decided that the hypothesized effectiveness of treat-
ment in each of the study groups may reach 85 %; for
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the purposes of calculating the effectiveness in the pla-
cebo group, this was taken as 45 % (on the basis of the
published data on the incidence of spontaneous CIN re-
gression) [33–35]. For β = 0.20 and α = 0.025, with the
assumed difference between the rates of the two study
groups being p2 − p1 = 0.40, we needed 26 subjects with
available data for analysis in each group.
Calculation of the sample size was performed as
follows:
n ¼ Zα þ Zβ
 2
 p1  1−p1ð Þð Þ þ p2  1−p2ð Þð Þ½ = p1−p2½ 2;
where n—sample size for each group; p1—rate in the
first group; p2—rate in the second group; p2 − p1—differ-
ence between rates of both groups; and Zα and Zβ—criti-
cal values of distribution corresponding to a given level
of error types 1 and 2, respectively.
A randomization list was provided by the Sponsor be-
fore the beginning of the study using SPSS Statistics ver-
sion 20.0.0 computer software. Block randomization was
used with a block size equal to 3; each block containing
two patients who were assigned different doses of the
active drug and one patient who was assigned a placebo.
The (blinded) treatment assignment procedure was car-
ried out by sending a fax to the Sponsor from the study
site. The fax contained a randomization request form
with information on the patient’s conformity with the in-
clusion/exclusion criteria. The Sponsor’s response, sent
by fax to the study site, consisted of a patient report
form with a unique identification number and drug
identification code on the packaging (in accordance with
the randomization sheet, packages of the preparation
contained an appropriate daily dose of the active drug or
a placebo). The randomization sheet was kept solely by
the Sponsor.
Forty-five days before the start of the study, the pa-
tients were screened: a process including the collection
of medical history, physical examination, clinical and
biochemical blood tests, urinalysis, electrocardiogram,
pelvic ultrasonography, colposcopy with photography,
and cervical biopsy. After clarification of the criteria for
inclusion and non-inclusion and the decision on whom
to include in the study, patients were randomized into
three groups: women from group 1 (n = 26) received an
intravaginal form of DIM in the dose of 200 mg/day
(one suppository of the study drug twice a day (BD)),
women from group 2 (n = 26) received an intravaginal
form of DIM in the dose of 100 mg/day or a placebo
(one suppository of the study drug and one suppository
of placebo per day), and women from group 3 (control
group (n = 26)) received only the placebo intravaginally
(one suppository with placebo BD). The course of treat-
ment lasted 180 days without a break (therapy was
terminated in patients who had complete CIN regression
according to histological examination on day 90 of the
study). Investigators and patients did not have any infor-
mation on whether the preparation being taken was the
active drug or a placebo. The study drug was “Cervikon-
DIM” (CJSC “IlmixGroup,” Russia) in the form of a vagi-
nal suppository. Each suppository was composed of the
active substance (3,3′-diindolylmethane 100 mg) and ex-
cipients (solid fat 1.9795 g, crospovidone 0.02 g, carmine
red dye 0.0005 g). The placebo suppository consisted of
solid fat 2.0795 g, crospovidone 0.02 g, and carmine red
dye 0.0005 g. The placebo was indistinguishable from
the active drug by its packaging, appearance, and or-
ganoleptic characteristics.
The study program included four visits: a baseline visit
(visit 1), then visits after 30 days (visit 2), 90 days (visit
3), and 180 days (visit 4) from the beginning of the ther-
apy. All women underwent a comprehensive survey dur-
ing all visits, including clinical blood and urine analyses,
electrocardiogram, cytology, and colposcopy with
photography.
The treatment efficacy was assessed by the proportion
of patients with complete CIN regression on the basis of
the histological examination of biopsy specimens of the
cervical lesions—the “gold standard” in CIN diagnosis.
Histological examination of biopsies of cervical lesions
was performed at the screening and after 90 and 180 days
of therapy. Withdrawal of biological samples for mor-
phological evaluation was carried out with colposcopic
visualization using special biopsy forceps for conchot-
omy in order to avoid coagulation of the biopsy’s edges.
A biopsy and histological study was performed on all the
patients after 90 days of therapy. In the absence of CIN,
the patient’s intake of the study drug was terminated.
Indicators as to whether patients who discontinued
treatment due to CIN recovery on day 90 should have a
biopsy after 180 days were the identification of an abnor-
mal transformation zone, aceto-white epithelium with
mosaic and/or punctate, iodine-negative epithelium,
abnormal blood vessels, or other potentially CIN-
associated features during the colposcopy after 180 days.
If the colposcopy (on day 180) was normal, a biopsy was
not performed in these patients 180 days after therapy
began, and it was assumed that they had made a full re-
covery from CIN. With patients who took the study
drug throughout the 180 days, a biopsy was carried out
in all cases at the end of the study.
Histological examination was performed sequentially
by two blinded independent laboratories: first of all by a
local one at the study site and then in a central labora-
tory. Where there were discrepancies in the results, the
final decision was taken by the central laboratory after
reading the opinion of the local laboratory. At the end of
the study, we counted the number of patients in whom
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the absence of CIN was confirmed according to the
morphological study. The persistence of CIN foci in bi-
opsies was considered a negative response to the
treatment.
The safety of the treatment was evaluated by detecting
adverse events (AEs). In addition, we assessed the pa-
rameters of vital body functions, the data from objective
studies and lab parameters at each patient’s visit: body
weight, body mass index, systolic blood pressure, dia-
stolic blood pressure, heart rate, respiratory rate, body
temperature, urinalysis (transparency, color, specific
gravity, pH, protein, glucose, ketone bodies, erythrocytes,
leukocytes, cylinders, salts, microorganisms), common
blood count (hemoglobin, red blood cell (RBC), white
blood cell (WBC), erythrocyte sedimentation rate), bio-
chemical blood analysis (total protein, creatinine, glu-
cose, alanine transaminase (ALT (GPT)), aspartate
transaminase (AST (GOT)), total bilirubin), and electro-
cardiogram (ECG). Deviations in laboratory parameters
and ECG were defined by the investigator as AEs if they
demanded, in his opinion, further diagnostic and/or
therapeutic measures.
We used a Kruskal-Wallis test to compare the homo-
geneity of the sample in the groups. A Clopper-Pearson
method was used for calculating 95 % binomial confi-
dence intervals. A mixed-designed ANOVA model for
the analysis of variance with repeated measures was used
to analyze the relationship between vital function varia-
tions and instrumental/laboratory data, treatment group,
and visit (change in time). To compare the frequencies
between the groups, we used Fisher’s exact test. For
planned comparisons of the efficacy, we calculated two-
sided significance. The assessment of significance was
performed following the stepwise procedure of the
Bonferroni correction modified by Holm [32]. This pro-
cedure involves carrying out tests with the order of sig-
nificance decreasing. The lower of two p values is tested
at the level of α/2. If the corresponding hypothesis is
rejected, then the second p value is tested at the level of
α; otherwise, both null hypotheses are accepted. The
total level of significance for this test procedure is equal
to α. Statistical analysis of the results of the study was
performed using SPSS Statistics software, version 20.0.0
(IBM Corporation).
Results
The women enrolled in the study were aged from 19 to
39. The average age of patients in group 1 was 26 years;
in groups 2 and 3, it was 27 years. Thus, CIN I–II oc-
curred most commonly in young women. This confirms
the results of numerous studies suggesting that CIN is
more prevalent in younger women than in older women.
Study participant statistics are shown in Table 1.
The selected groups were virtually homogeneous in
terms of baseline comparative values at the time of
screening. The demographic characteristics of the study
groups (for each group) and the total sample analysis are
presented below (Tables 2 and 3). When preparing sum-
mary tables in this section, we did not include patients
who were withdrawn prior to initiating the therapy.
Table 1 Distribution of the subjects into groups and the study population
Intervention Group Total
DIM DIM Placebo
100 mg/day 200 mg/day
Number of patients enrolled 26 26 26 78












Date of the last visit of the last patient 4 April 2014 5 April 2014 15 April 2014
Eliminated from the study due to withdrawal of consent to participate in the study prior to
receiving the first dose of the drug and excluded from the analysis (both safety and efficacy)
1 2 3 6
Eliminated from the study due to withdrawal of consent to participate in the study after the
beginning of therapy
2 4 4 10
Ceased to meet the criteria for participation in the study 0 0 0 0
Excluded from the study for safety reasons ahead of schedule 2 1 1 4
Completed visit procedure in 90 days of treatment in accordance with the study protocol
and included in the efficacy analysis
22 20 19 61
Stopped taking the drug due to CIN recovery after 90 days of therapy 15 17 10 42
Completed visit procedures after 180 days of treatment in accordance with the study protocol
and included in the efficacy analysis
21 19 18 58
CIN cervical intraepithelial neoplasia, DIM 3,3′-diindolylmethane
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The study groups had no significant differences in
terms of key demographic indicators, gynecological his-
tory, and vital signs, which suggests that the study sam-
ple was homogeneous. The findings from physical
examinations were normal in all the subjects.
When comparing the efficacy of the therapy (CIN re-
gression on histological examination) after 180 days, we
found that in the treatment group receiving a 100 mg/day
dose of DIM, the therapy efficacy was higher than that in
the placebo group (Fig. 1), amounting to 90.50 % (confi-
dence interval (CI) 95 %: 69.62–98.83 %) and 61.10 % (CI
95 %: 35.75–82.70 %), respectively. In the group receiving
a 200 mg/day dose of DIM, the therapy efficacy was higher
than that in the placebo group (Fig. 1), amounting to
100.0 % (CI 95 %: 82.35–100.00 %) and 61.10 % (CI 95 %:
35.75–82.70 %), respectively.
The smallest p value for comparing the frequency of
CIN absence between groups is 0.003. Thus, taking into
account the Holm correction, first of all, we tested the
H02 hypothesis at the level of α = 0.025 (Table 4). Test-
ing the H02 hypothesis has shown that these differences
are statistically significant, and the null hypothesis is
rejected. Subsequently, testing of the H01 hypothesis
yielded p = 0.0361 (taking in account the Holm correc-
tion amended by Hill); the difference was thus statisti-
cally significant, and the null hypothesis was rejected at
the pre-determined level of α = 0.05. Thus, the efficacy
of the study therapy is considered to be statistically
Table 2 Baseline demographic characteristics of the study groups and in the total sample of the study (e.g., race, smoking, history
of the disease, comorbidities)
Index Group Total
DIM DIM Placebo
100 mg/day 200 mg/day
Rate % in group Rate % in group Rate % in group Rate % of all
Race Caucasian 24 100 23 100 23 100 70 100
Other 0 0 0 0 0 0 0 0
Smoking No 23 92 24 100 23 92 70 94.6
Yes 2 8 0 0 2 8 4 5.4
Significant diseases in anamnesis No 20 87.0 18 78.3 19 82.6 57 82.6
Yes 3 13.0 5 21.7 4 17.4 12 17.4
The presence of comorbidities No 18 78.3 17 74.0 20 87.0 55 79.7
Yes 5 21.7 6 26.0 3 13.0 14 20.3
DIM 3,3′-diindolylmethane




100 mg/day 200 mg/day
Age, years 27 ± 5 27 ± 3 27 ± 5 27 ± 5
Height, cm 167 ± 6 166 ± 7 165 ± 5 166 ± 5
Body weight, kg 63 ± 11 59 ± 10 64 ± 13 62 ± 11
Body mass index 23 ± 4 22 ± 3 23 ± 5 23 ± 4
Systolic blood pressure, mmHg 112 ± 8 110 ± 7 111 ± 9 111 ± 8
Diastolic blood pressure, mmHg 73 ± 6 68 ± 5 71 ± 5 71 ± 6
Heart rate, beats per minute 73 ± 5 72 ± 6 72 ± 7 73 ± 6
Respiratory rate, breaths per minute 16 ± 2 17 ± 4 17 ± 4 17 ± 3
Body temperature, °C 37 ± 0 37 ± 0 37 ± 0 37 ± 0
Age of menarche, years 13 ± 1 13 ± 1 14 ± 2 13 ± 1
Duration of menstruation, days 5 ± 1 5 ± 1 5 ± 1 5 ± 1
Duration of the menstrual cycle, days 29 ± 2 29 ± 4 29 ± 2 29 ± 3
DIM 3,3′-diindolylmethane
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significantly higher than the placebo therapy in each of
the experimental groups.
In total, during this study, we recorded 34 AEs (13 in
the treatment group taking DIM in the dose of 100 mg/
day, 14 in the treatment group taking DIM in the dose
of 200 mg/day, and 7 in the placebo group). We ex-
cluded patients who were withdrawn before taking the
first dose of the study drug from the safety analysis. The
developed undesirable phenomena were distributed rela-
tively evenly in the patients during the whole study
(Table 5).
In the placebo group, AEs occurred in 22 % of patients
(5 of 23 subjects, CI 95 %: 7.5–43.7 %); in the group
treated with a 100 mg/day dose of DIM, AEs were re-
ported in 40.0 % of patients (10 of 25 subjects, CI 95 %:
21.1–61.3 %); and in the group treated with a 200 mg/
day dose of DIM, AEs were reported in 42.0 % of pa-
tients (10 of 24 subjects, CI 95 %: 22.1–63.4 %). We
found significant differences in the number of patients
who developed AEs between the groups treated by the
active drug as compared to the placebo group (DIM
100 mg/day, p = 0.0045; DIM 200 mg/day, p = 0.0019).
In total, we revealed 23 kinds of AEs, out of which 3
were associated with particular changes in urinalysis, 5
were associated with variations in the clinical and bio-
chemical blood analysis, 2 were associated with ECG
changes, 5 were associated with subjective sexual func-
tion disorders (discomfort in the vagina, etc.), and 8
were associated with other types of AEs (Table 6).
In 4 cases out of the 34 AEs, the researcher at the
local site considered that the AEs had developed as a re-
sult of the therapy by the study drug (burning, itching of
the vagina—2 cases; urticaria—1 case; acute respiratory
viral infection—1 case). Among other AEs, in 5 cases,
there was a probable relationship between the study
drug intake and AE development from the researcher’s
perspective; in 5 cases, the relationship was possible; in
10 cases—doubtful; in 1 case—conditional; and in 9
cases, the investigator was unable to classify the relation-
ship with AEs. In 18 cases out of 34, no AE therapy was
performed; in 16 cases, specialized treatment was con-
ducted. The severity of AEs was marked as “moderate”
for one case of acute respiratory viral infection; in one
case, there was an increase in the amount of white vagi-
nal discharge; in one case, there was myocardial hypoxia
on the electrocardiogram; there were two cases of burn-
ing and itching in the vagina; and in one case, researches
found profuse, flaky discharge from the genital tract. In
all other 28 cases, the severity of the AE was marked as
“mild.” In four cases, the study was terminated prema-
turely due to AEs: one case (burning and itching in the
vagina) in the treatment group taking DIM in the dose
Fig. 1 Effectiveness of the therapy according to the data of histological examination (90–180 days of treatment)





















No 2 9.5 0.0361 0 0 0.003 7 38.9
Yes 19 90.5 19 100 11 61.1
CIN cervical intraepithelial neoplasia, DIM 3,3′-diindolylmethane
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100 mg/day 200 mg/day
(n = 25) (n = 24) (n = 23)
Rates Percent 95 % CI Rates Percent 95 % CI Rates Percent 95 % CI
Visit 1 0 0.0 0.0–13.7 1 4.2 0.1–21.1 3 13.0 2.8–33.6
Visit 2 7 28.0 12.1–49.4 3 12.5 2.7–32.4 1 4.3 0.1–22.0
Visit 3 2 8.0 1.0–26.0 6 25.0 9.8–46.7 1 4.3 0.1–22.0
Visit 4 3 12.0 2.6–31.2 4 16.7 4.7–37.4 2 8.7 1.1–28.0
AE adverse events, CI confidence interval, DIM 3,3′-diindolylmethane
Table 6 Types of adverse events, recorded in the study groups
AEs reported in the patient (in alphabetical order) Group Total
DIM DIM Placebo
100 mg/day 200 mg/day
Frequency % in group Frequency % in group Frequency % in group Frequency % of all
Bacteriuria, leukocyturia, proteinuria 0 0.0 1 7.1 0 0.0 1 2.9
Myocardial hypoxia on ECG 0 0.0 1 7.1 0 0.0 1 2.9
Dysbiosis of the vagina 0 0.0 1 7.1 0 0.0 1 2.9
Discomfort when using the drug 1 7.7 0 0.0 0 0.0 1 2.9
Burning, itching of the vagina 4 30.8 1 7.1 0 0.0 5 14.7
Loose stool 1 7.7 0 0.0 0 0.0 1 2.9
Delay of menstruation 0 0.0 1 7.1 0 0.0 1 2.9
Slower growth of hair on the head, body 0 0.0 1 7.1 0 0.0 1 2.9
Ketone bodies in urine 0 0.0 1 7.1 0 0.0 1 2.9
Urticaria 1 7.7 0 0.0 0 0.0 1 2.9
Leukocytosis in the cervical smear 0 0.0 1 7.1 0 0.0 1 2.9
Abundant flocculent discharge from the
genital tract
0 0.0 2 14.3 1 14.3 3 8.8
Acute respiratory viral infection 1 7.7 1 7.1 3 42.9 5 14.7
Increased blood pressure 0 0.0 1 7.1 0 0.0 1 2.9
Increased plasma levels of ALT (GPT) and AST (GOT) 0 0.0 2 14.3 0 0.0 2 5.9
Increased erythrocyte sedimentation rate 1 7.7 0 0.0 0 0.0 1 2.9
Proteinuria 1 7.7 0 0.0 0 0.0 1 2.9
Decrease in hemoglobin in the blood 0 0.0 0 0.0 1 14.3 1 2.9
Decrease in plasma creatinine 1 7.7 0 0.0 0 0.0 1 2.9
Reduced white blood cell count 0 0.0 0 0.0 1 14.3 1 2.9
Dryness in the vagina during sexual intercourse 1 7.7 0 0.0 0 0.0 1 2.9
Increased amount of white vaginal discharge 0 0.0 0 0.0 1 14.3 1 2.9
Shortening of the AVC 1 7.7 0 0.0 0 0.0 1 2.9
Total 13 14 7 34
AE adverse events, ALT (GPT) alanine transaminase, AST (GOT) aspartate transaminase, AVC (atrioventricular conduction) , DIM 3,3′-diindolylmethane,
ECG electrocardiogram
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of 200 mg/day, two cases (burning and itching in the va-
gina, urticaria) in the treatment group taking DIM in the
dose of 100 mg/day, and one case (acute respiratory viral
infection) in the placebo group.
No serious AEs were recorded in this study.
In the vast majority of cases, there were no statistically
significant changes in these indicators during the therapy,
and no relationship with the study drug was revealed, ac-
cording to the analysis of parameters of vital body func-
tions, the data from objective medical examinations, and
instrumental/laboratory parameters in the study groups by
visit dynamics. A relationship has been identified regarding
systolic and diastolic blood pressure (we found the impact
of the group effect to be p = 0.021 and p = 0.010, respect-
ively; the values were lower in the treatment group taking a
200 mg/day dose of DIM) and in the plasma levels of ALT
and AST (it was shown that there is an impact of the group
effect: p = 0.034 and p = 0.018, respectively; the values were
lower in the treatment group taking a 200 mg/day dose of
DIM).
Discussion
Currently, there is no single approach to the treatment of
CIN I and/or CIN II in young women. The existing stan-
dards justify an aggressive radicalism, which often leads to
the disruption of reproductive function. CIN is most preva-
lent in younger women. We have confirmed this thesis in
this study as well. Destructive methods of CIN treatment
are invasive and traumatic, despite their proven efficacy.
They often disrupt the patient’s reproductive plans. At the
same time, waiting for long-term follow-up to check for
spontaneous regression of CIN and the tactics of non-
interference (especially when the patient cancels visits to
the doctor) can permit further progression of the disease
process. Therefore, searching for an adequate conservative
treatment is an important issue in the management of CIN
I–II. This approach could be very valuable and is in accord-
ance with the EPMA (European Association for Predictive,
Preventive and Personalized Medicine) position in the can-
cer prevention field [36]. A number of randomized,
placebo-controlled clinical trials have reviewed in detail the
relationship between the use of oral I3C and DIM sub-
stances in CIN patients and noted an improvement in the
course of the disease during treatment with these
substances.
The study of Bell et al. involved 17 women diagnosed
with CIN II–III [20]. For 12 weeks, each of them took
I3C per os in a dose of 200 or 400 mg per day. At the
end of the study, there was complete CIN regression in
four of the eight patients who received a 200 mg/day
dose of I3C and in four of the nine patients taking a
400 mg/day dose of I3C. At the same time, in all the
women with complete CIN regression, there was a
significant increase in urinary excretion of the estradiol
2-OHE1 metabolite.
In a clinical study performed by Del Priore et al., it was
shown that the use of DIM per os in the dose of 2 mg/kg/
day caused a clinical improvement in CIN II–III patients.
However, no statistically significant differences between
the experimental and control groups were revealed [37].
Probably, this result occurred due to the low bioavailabil-
ity of the test DIM formulation. The data from another
clinical study supports this explanation: researches tested
high doses of formulated BioResponse-DIM (a crystalline
diindolylmethane in a microfine starch whose bioavailabil-
ity is 1.5–2 times higher than that of non-formulated
DIM). At the same time, complete CIN II and CIN III re-
covery was observed [38].
Results of a big DIM clinical trial in CIN treatment
were reported by Castañon et al. in 2012 [39]. As treat-
ment intervention, 150 mg of oral DIM formulation or
placebo (one time in a day) was used, and no statistically
significant difference between groups was detected. But
the serious disadvantage of this study was that baseline
CIN was not histologically proven; beyond it, half-life of
DIM formulation (3 h) might be too small for one time
in a day administration. Our general suggestion is that a
relatively higher DIM concentration is necessary for CIN
treatment, and so, topical DIM administration may be
preferable.
In addition, experimental diindolylmethane studies in
vitro and in vivo provide a reasonable basis for its clin-
ical evaluation as a means of prevention and treatment
of cervical cancer [22, 23, 28, 40–42]. So, we can assume
that a drug based on an active DIM substance should
display high activity against transformed cells of the cer-
vical epithelium.
Our study showed that the intravaginal use of DIM in
doses of 200 and 100 mg/day for 90–180 days was ac-
companied by a high rate of CIN I–II reversion. Un-
doubtedly, this non-invasive method is very promising
for the conservative treatment of CIN in women of re-
productive age, demonstrating a careful and sparing ap-
proach which does not involve damage to the cervix.
Also, this method has been proved pathogenetically,
given the mechanism of DIM’s effect on cell transform-
ation following HPV infection and the production of the
E6 and E7 proteins. Local application of DIM, unlike the
systemic use, is usually characterized by a higher level of
safety and tolerability. The studied form of vaginal sup-
positories for treating CIN I–II may be considered the
most safe and effective method of treatment, with min-
imal and rare side effects. This also supports patient
compliance, taking into account the location of the af-
fected area and topical use of the drug.
Nevertheless, this study has some limitations. Particu-
larly, it involved a small number of patients. In addition,
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the data obtained can only be considered preliminary in
relation to the selection of the preferred mode of treat-
ment (daily dose and duration of treatment). Another
general limitation of our trial design is that the investiga-
tor could have missed cervical lesions during colposcopy
on day 180 and thus had not taken the biopsy. If this
took place, it could bias the results.
Previously, a phase I clinical trial of the drug was per-
formed (the data were not published). We successively
included four groups of 10 volunteers who used an
intravaginal form of the drug in an increasing dosage (in
doses of 50 mg once a day (QD), 100 mg QD, 200 mg
QD, and 100 mg four times a day (QID) with intervals
of 0.5 h). In the study, we observed 14 AEs in 10 volun-
teers. Among the AEs were the following: increased
erythrocyte sedimentation rate (seven cases), decreased
erythrocyte sedimentation rate (one case), increase in
the level of total bilirubin (one case), and increased ALT
and AST (one case). No serious AEs were observed. In
all cases, the researcher estimated the intensity of AEs as
“minor.” The study did not reveal any significant effect
of the study drug on vital signs, ECG, clinical and bio-
chemical blood tests, and urinalysis.
In the current phase IIa study, we have found signifi-
cant differences in the treatment groups taking DIM as
compared with the placebo group by the number of pa-
tients who developed AEs (DIM 100 mg/day, p = 0.0045;
DIM 200 mg/day, p = 0.0019). Of the 34 cases of AEs
identified in this study, in 4 cases, the researchers
claimed they were related to the received drug (burning
and itching in the vagina—2 cases; urticaria—1 case;
acute respiratory viral infection—1 case). Nevertheless, a
drug effect leading to the development of respiratory
viral infections is improbable, because of the lack of data
on potential mechanisms of this phenomenon. In the
study groups, there were no significant changes in la-
boratory parameters during the treatment (or they were
not clinically significant in case of blood pressure) and
there was no relationship with the study drug with the
exception of ALT and AST. The study drug has shown
the dose-related group effect (p = 0.034 and p = 0.018,
respectively, for the groups of patients taking 100 and
200 mg/day doses) on the level of these transaminases.
Increased AST and ALT levels in a number of patients
have been recognized by some researchers to be clinic-
ally significant and reported as AEs. However, it should
be noted that in virtually all cases this increase was tran-
sient. Only two patients had elevated levels of transami-
nases at the time of visit 4 (with an increased level of
only one transaminase). Itching and burning in the va-
gina was noted in the patients treated with placebo and
active suppositories; therefore, the response of the mu-
cosal epithelium to excipients used in suppositories, as
well as individual sensitivity, cannot be excluded.
However, in order to clarify the presence of hepatotox-
icity and the local irritating action of the drug, we need
to perform further studies with a larger number of pa-
tients. In addition, the small number of patients receiv-
ing the study drug overall may have limited our ability
to identify relatively rare side effects of the drug. Also, a
higher rate of local AEs may have led to an “unblinding”
effect if the investigator might have guessed that the pa-
tient was on active treatment. It may be another limita-
tion of our trial too. Therefore, further clinical studies
are needed to detect the efficacy and safety of the drug.
Conclusions
The presented results of the safety and efficiacy of the
Cervikon-DIM, obtained within the Phase IIa of the
double-blind, randomized, placebo-controlled multicen-
ter study, confirm efficacy and favorable safety profile of
the investigated drug. Thus, the use of diindolylmethane
in the form of intravaginal suppositories can be effective
in patients with CIN I-II, and is not accompanied by
clinically significant side effects.
Expert recommendations
Drug development based on diindolylmethane’s ability to
prevent cancer promotion is a technically complicated,
but very promising, issue. As oral medications are pref-
erable for prevention of most cancer localization, in
some cases, topical formulations may be more appropri-
ate. Using this substance in a suppository form could be
useful for CIN treatment, especially in young women. As
it is stated in the EPMA white paper [43], cervical histo-
pathology is useful as a predictive biomarker for cervical
cancer. So, a prevention strategy in young patients may
be based on CIN conservative treatment with a topical
drug containing diindolylmethane.
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